M emory services in the UK are responsible for the assessment and diagnosis of people presenting with cognitive impairment. The Department of Health in its most recent mandate to NHS England outlines the requirement that at least two thirds of people with dementia receive a diagnosis. 1 Considering the reported increase in referral rates to memory services, maintaining high standards of care including accurate diagnosis is vital in ensuring that people receive appropriate, timely and individualised support. 2 An essential part of all memory assessments, as recommended by the Royal College of Psychiatrists' Memory Service National Accreditation Programme (MSNAP) initiative, includes a review of physical health and medications to identify potential reversible causes of cognitive change. 3 This is important, as a diagnosis of dementia should be made only in the absence of other causes. 4 In their diagnostic criteria for Alzheimer's disease, the National Institute on Aging and the Alzheimer's Association (NIA-AA) outline that a diagnosis of dementia should not be given if there is the possibility of medication having a significant effect on cognition. 5 Drugs with anticholinergic properties are most likely to contribute to cognitive decline but other groups of commonly prescribed medication such as opioid analgesics, corticosteroids and sedating medications, eg benzodiazepines, antihistamines, sedative antidepressants and antipsychotics, may also be responsible. In this audit we use a list of commonly prescribed confusion-inducing drugs (CIDs) derived from the American Geriatrics Society Beers Criteria as a tool to review practice. Within the Trust MAS, the four localities follow a similar care pathway: patients are referred into the service by General Practitioners (GPs). All patients undergo a core assessment by a memory nurse who obtains a targeted history and completes an Addenbrooke's Cognitive Examination (ACE). 8 The initial assessment is then discussed at a multidisciplinary team (MDT) meeting, which is attended by an older adult psychiatrists among other professionals. Once patients have undergone all necessary investigations, they are seen by a doctor at a diagnostic appointment where their diagnosis and management are discussed. Those patients who are prescribed anti-dementia medication will be offered post-diagnostic follow-up.
Within the described care pathway, we identified five points at which opportunities arise for the identification and review of CIDs: the GP referral, the core assessment, the MDT discussion, the initial diagnostic appointment and follow-up appointments. Letters and documentation from these points of contact were reviewed in each case.
The data collection tool gathered information on age, gender, duration of cognitive symptoms, ACE score, final diagnosis, CID prescriptions and CID review. To meet the audit standard, clinicians had to have documented a statement that they had noted the CID prescription and advised that it may be contributing to the patient's cognitive symptoms. Patients who were prescribed more than one CID had to have all their CIDs reviewed to meet the audit standard. For the re-audit, a review of a CID was only included if it was prescribed following the interventions carried out in March 2017 (outlined below). This was done so that the re-audit data reflected practice after the interventions.
The interventions carried out in March 2017 included presenting and discussing the results of the initial audit at the old age psychiatry academic meeting attended by all medical staff working in MAS. The results were then disseminated via email to all medical staff and team managers across the four localities. A laminated aide-memoire of commonly prescribed CIDs was produced (see Figure 1) and then distributed to all medical staff and Community Dementia Nurses (CDNs).
After the re-audit, the two sets of data were compared. An unpaired t-test was preformed to compare differences between the means calculated from the June 2016 and June 2017 data. A chisquared test was used to compare differences between categorical data. All analyses were carried out using Stata Version 14 (9). Table 2 demonstrates that the two samples were also similar with respect to the number of patients who were on a CID and the total number of CIDs prescribed. In 2017, of the drugs with high anticholinergic cognitive burden (ACB), nine were antidepressants (all amitriptyline), two were urinary system drugs (oxybutynin and darifenacin), and one was antiparkinsonian (trihexyphenidyl). In comparison, in 2016, there was a wider distribution of drugs within this category: five were antidepressants (amitriptyline x2, clomipramine x2 and paroxetine), two were antipsychotics (olanzapine and quetiapine), two were urinary system drugs (both oxybutynin) and one was antiparkinsonian (procyclidine). There was a similar distribution of sedatives encompassing benzodiazepines, z-drugs and sedating antihistamines between the two audits.
In 2016, across all localities, only 29% of patients taking a CID had them reviewed. This improved to 37% in the 2017 re-audit but this change was not statistically significant In Table 2 , we have included the range of CID reviews across different localities, with 56% being the best performance in 2016 and 100% in 2017. Both best performances were observed in the same locality.
Discussion
Susceptibility to the adverse effects of medication and drug interactions become increasingly likely as people age. Drug sensitivity is in part a consequence of altered brain neurochemistry and drug handling including pharmacokinetic and pharmacodynamic changes. 10, 11 This risk is further exacerbated by polypharmacy which commonly occurs in older adult populations who are frequently prescribed medications for multiple health conditions. Polypharmacy has been associated with negative health care outcomes as well as cognitive and functional decline. 12 It is therefore apparent that the changes caused by medication use have the potential to mimic the core features of a dementia syndrome or at least have an additive affect to existing cognitive impairment. This audit cycle demonstrates that opportunities are being missed within MAS to review medications that can have cognitive side-effects. Misinterpreting cognitive complaints as symptoms of a dementia syndrome rather than adverse effects of medication remains a possibility without thorough and comprehensive assessment. Stopping or reducing doses of drugs with significant anticholinergic burden may reduce the likelihood of adverse r e a c t i o n s a n d c o n s e q u e n t l y improve quality of life; improvements in cognition are possible although truly reversible dementia as a consequence of medication is uncommon.
11 Medication reviews may not necessarily lead to medications being stopped, particularly in the case of treatment for existing co-morbidities, but they will prompt clinicians and patients to reassess whether the intended benefits are being achieved. Involvement of patients and their families throughout this process is essential in ensuring that they have autonomy over treatment decisions.
Despite our interventions, the audit results indicate that there wasn't a statistically significant change in the proportion of CIDs being reviewed between the initial audit and re-audit. When the results of the initial audit were presented to MAS medical staff, one of the reasons considered to be contributing to the poor performance was uncertainty about who should be responsible for carrying out the review given that the primary prescriber is often the GP. Other reasons identified included reluctance in highlighting medications to GPs, lack of knowledge about identification of CIDs and not recording CIDs when they were not deemed as having a significant impact on cognition. We acknowledge that there were limitations to the audit methodology. To maintain consistency across the initial and re-audit, only the records of patients seen by consultants were audited. If we had included all patients assessed by MAS medical staff, this is likely to have been more representative of the overall practice of the service. Looking at the proportion of CIDs reviewed, one locality performed noticeably better than the three other localities in the re-audit (100% vs. a range of 0-33%, r e s p e c t i v e l y ) . T h i s c a n b e explained by one author leading the MAS team in that locality; this relationship to the audit may have had a positive bias.
There may have been a significant improvement in the re-audit results if the interventions were targeted at primary care, especially as they are increasingly becoming involved in the diagnosis and management of dementia.
2 A pharmacy-based intervention may also have been more effective. In an audit assessing whether service users in an acute hospital setting received correct pharmacological treatment, a pharmacy service intervention resulted in an improvement in practice. 13 Pharmacy services in 2gether NHS Foundation Trust do not routinely contribute to the assessment of MAS patients. However, with modernisation of pharmacy services there may be scope in future for electronic prescribing systems to flag up CIDs thus highlighting to MAS medical staff when a review is required.
A Screening Tool of Older People's Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) known as the S T O P P / S TA RT c r i t e r i a h a s proven effective at identifying inappropriate prescribing in older people.
14 It builds upon Beers' Criteria recommendations which has been criticised for identifying only a small proportion of inappropriate prescribing practices and for lack of applicability outside of North America. 15 The aid memoire produced following the initial audit as an intervention to assist MAS medical staff in the identification of CIDs could be revised to incorporate the START principles. This could include a resource detailing alternative prescribing options. This additional intervention may enable MAS medical staff to feel more confident in highlighting to GPs when a medication review is needed
Conclusion
Despite the lack of statistically significant results, the audit highlights the importance of reviewing prescriptions for CIDs within memory services and barriers to improving clinical practice. The re-audit results suggest that continued education on the potential impact medications can have on cognition is needed both within MAS and Primary Care. Further work is required locally to improve the practice of CID identification.
